Gilead Finalizes $3.15B Tubulis Acquisition, Adds Key Oncology ADC Assets
GILD sits 24% above its 52-week low of $104.46.
Summary
Gilead Sciences has completed its acquisition of Tubulis for $3.15 billion upfront, with potential milestone payments up to $1.85 billion. This strategic move significantly expands Gilead's oncology portfolio by adding next-generation antibody-drug conjugates (ADCs), including TUB-040 for platinum-resistant ovarian cancer and TUB-030 for solid tumors. The acquisition follows Gilead's recent aggressive M&A activity, including the Arcellx deal, and a $3 billion senior notes offering to fund these expansions. While Q1 earnings already factored in substantial IPR&D charges from recent acquisitions, the completion of this specific deal confirms the deployment of significant capital into a key growth area.
At the time of this announcement, GILD was trading at $129.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162.3B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.